Skip to main content
Industry News
EU OKs crizanlizumab to prevent sickle cell disease pain
11/5/2020

Novartis' Adakveo, or crizanlizumab, has been approved by the European Commission in combination with hydroxyurea for the prevention of recurrent painful vaso-occlusive crises in people with sickle cell disease ages 16 and older.

Full Story: